Regulators split on antimalarials for COVID-19.
Identifieur interne : 001A02 ( Main/Curation ); précédent : 001A01; suivant : 001A03Regulators split on antimalarials for COVID-19.
Auteurs : Susan JaffeSource :
- Lancet (London, England) [ 1474-547X ] ; 2020.
Descripteurs français
- KwdFr :
- Agrément de médicaments (législation et jurisprudence), Agrément de médicaments (organisation et administration), Antipaludiques (effets indésirables), Antipaludiques (ressources et distribution), Antipaludiques (usage thérapeutique), Betacoronavirus (MeSH), Chloroquine (effets indésirables), Chloroquine (ressources et distribution), Chloroquine (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (ressources et distribution), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (législation et jurisprudence), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Union européenne (MeSH), États-Unis (épidémiologie).
- MESH :
- effets indésirables : Antipaludiques, Chloroquine, Hydroxychloroquine.
- législation et jurisprudence : Agrément de médicaments, Pandémies.
- organisation et administration : Agrément de médicaments.
- ressources et distribution : Antipaludiques, Chloroquine, Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antipaludiques, Chloroquine, Hydroxychloroquine.
- épidémiologie : Infections à coronavirus, Pneumopathie virale, États-Unis.
- Betacoronavirus, Humains, Union européenne.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Antimalarials (adverse effects), Antimalarials (supply & distribution), Antimalarials (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (adverse effects), Chloroquine (supply & distribution), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug Approval (legislation & jurisprudence), Drug Approval (organization & administration), European Union (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (supply & distribution), Hydroxychloroquine (therapeutic use), Pandemics (legislation & jurisprudence), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH), United States (epidemiology).
- MESH :
- chemical , adverse effects : Antimalarials, Chloroquine, Hydroxychloroquine.
- chemical , supply & distribution : Antimalarials, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Antimalarials, Chloroquine, Hydroxychloroquine.
- geographic , epidemiology : United States.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- legislation & jurisprudence : Drug Approval, Pandemics.
- organization & administration : Drug Approval.
- Betacoronavirus, COVID-19, European Union, Humans, SARS-CoV-2.
DOI: 10.1016/S0140-6736(20)30817-5
PubMed: 32278373
PubMed Central: PMC7146712
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A02
Links to Exploration step
pubmed:32278373Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Regulators split on antimalarials for COVID-19.</title>
<author><name sortKey="Jaffe, Susan" sort="Jaffe, Susan" uniqKey="Jaffe S" first="Susan" last="Jaffe">Susan Jaffe</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32278373</idno>
<idno type="pmid">32278373</idno>
<idno type="doi">10.1016/S0140-6736(20)30817-5</idno>
<idno type="pmc">PMC7146712</idno>
<idno type="wicri:Area/Main/Corpus">001A02</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A02</idno>
<idno type="wicri:Area/Main/Curation">001A02</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Regulators split on antimalarials for COVID-19.</title>
<author><name sortKey="Jaffe, Susan" sort="Jaffe, Susan" uniqKey="Jaffe S" first="Susan" last="Jaffe">Susan Jaffe</name>
</author>
</analytic>
<series><title level="j">Lancet (London, England)</title>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (adverse effects)</term>
<term>Antimalarials (supply & distribution)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (adverse effects)</term>
<term>Chloroquine (supply & distribution)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Drug Approval (legislation & jurisprudence)</term>
<term>Drug Approval (organization & administration)</term>
<term>European Union (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (supply & distribution)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (legislation & jurisprudence)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agrément de médicaments (législation et jurisprudence)</term>
<term>Agrément de médicaments (organisation et administration)</term>
<term>Antipaludiques (effets indésirables)</term>
<term>Antipaludiques (ressources et distribution)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Chloroquine (effets indésirables)</term>
<term>Chloroquine (ressources et distribution)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (ressources et distribution)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Pandémies (législation et jurisprudence)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Union européenne (MeSH)</term>
<term>États-Unis (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Antimalarials</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antipaludiques</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en"><term>Drug Approval</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr"><term>Agrément de médicaments</term>
<term>Pandémies</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Agrément de médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Drug Approval</term>
</keywords>
<keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Antipaludiques</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>États-Unis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>European Union</term>
<term>Humans</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Union européenne</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32278373</PMID>
<DateCompleted><Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>395</Volume>
<Issue>10231</Issue>
<PubDate><Year>2020</Year>
<Month>04</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Lancet (London, England)</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulators split on antimalarials for COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>1179</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0140-6736(20)30817-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(20)30817-5</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaffe</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
<QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005062" MajorTopicYN="N">European Union</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000331" MajorTopicYN="N">legislation & jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32278373</ArticleId>
<ArticleId IdType="pii">S0140-6736(20)30817-5</ArticleId>
<ArticleId IdType="doi">10.1016/S0140-6736(20)30817-5</ArticleId>
<ArticleId IdType="pmc">PMC7146712</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001A02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:32278373 |texte= Regulators split on antimalarials for COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32278373" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |